头孢他啶/舒巴坦对细菌感染小鼠败血症的体内抗菌作用研究

In Vivo Activity of Ceftazidime/Sulbactam in the Experimental Model of Mouse Septicemia Infected by Bacteria

目的:评价头孢他啶/舒巴坦对细菌感染小鼠的体内抗菌作用。方法:以0.5mlMLD感染小鼠,建立小鼠败血症实验模型。结果:对于革兰阴性杆菌,头孢他啶/舒巴坦的体内抗菌作用明显优于单独使用头孢他啶或舒巴坦,其ED50值与单药ED50值相比,具有非常显著差别（P<0.01）。对于大肠杆菌,单独使用头孢他啶的ED50和ED95值是加入舒巴坦后的5.5～11.9倍;对于阴沟肠杆菌,单独使用头孢他啶的ED50和ED95值是加入舒巴坦后的2.5～6.6倍;对枸橼酸杆菌,单独使用头孢他啶的ED50和ED95值是加入舒巴坦后的2.8～14.4倍。对于革兰阳性菌,联合制剂的体内抗菌作用略优于单独使用头孢他啶。两株金黄色葡萄球菌中一株联合制剂ED50值比单药显著降低（P<0.05）。两配比间均无显著差别（P>0.05）。结论:对于耐头孢他啶的革兰阴性杆菌,两药具有很好的体内协同作用,舒巴坦可以起到抑酶增效的作用。

OBJECTIVE: Evaluate in vivo activity of ceftazidime/sulbactam in the experimental therapy of mouse septicemia. METHODS: The mice were challenged ip with 0.5ml IMLD bacteria and the experimental model of mouse septicemia was established. RESULTS: In vivo activity of ceftazidime/sulbactam was stronger than those of ceftazidime or sulbactam alone with statistically significant difference (P<0.01) against gram-negative bacilli. In infections with Escherichia coli, ED50 and ED95 of ceftazidime were 5.5-11.9 times higher than ceftazidime/ sulbactam. In infections with Enterobacter cloacae, ED5() and ED95 of ceftazidime were 2.5-6.6 times higher than ceftazidime/ sulbactam. In infections with Cirobacter spp., ED50 and ED95 of ceftazidime were 2.8-14.4 times higher than ceftazidime/sulbactam. Against gram-positive cocci, in vivo activity of ceftazidim/sulbactam was slightly more than ceftazidime alone. ED50 value of ceftazidime/sulbactam low than that of ceftazidime with significant difference(P<0.05) against one of the two staphylococcus aureus. There was no different at two rations. CONCLUSION: Ceftazidime/sulbactam showed a good in vivo synergism for gram negative bacilli.